Therapeutic Advances in Childhood Leukemia Consortium

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Therapeutic Advances in Childhood Leukemia Consortium sits in the top decile of US sponsors by registered trial count (#772 of 15,742 sponsors by registered trial count).

19 total trials 2 currently recruiting 8 completed early-phase tilt top decile by trial count

Therapeutic Advances in Childhood Leukemia Consortium: 19 sponsored US clinical trials, 2 recruiting.

Therapeutic Advances in Childhood Leukemia Consortium sponsors 19 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 8 completed. 0 of these trials are in Phase 3-4 (later-stage) and 19 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Lymphoblastic Leukemia, Acute, Childhood, with 2 trials.

Top-decile sponsor footprint

Therapeutic Advances in Childhood Leukemia Consortium ranks in the top decile of sponsors by registered trial count (#772 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 0/100

8 of 16 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (50.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

19 total, page 1 of 1

RECRUITING Phase 1

A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia

NCT05849662
RECRUITING Phase 1

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

NCT05476770
ACTIVE NOT RECRUITING Phase 1

PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

NCT03817320
COMPLETED Phase 1

Epigenetic Reprogramming in Relapse/Refractory AML

NCT03263936
COMPLETED Phase 1

Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy

NCT02879643
COMPLETED Phase 1

A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma

NCT01614197
TERMINATED Phase 1

Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia

NCT01743807
COMPLETED Phase 1

A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML

NCT01861002
TERMINATED Phase 1

A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL

NCT01483690
COMPLETED Phase 1

AC220 for Children With Relapsed/Refractory ALL or AML

NCT01411267
COMPLETED Phase 1

A Study Of Panobinostat In Children With Refractory Hematologic Malignancies

NCT01321346
TERMINATED Phase 1

EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)

NCT01186328
TERMINATED Phase 2

Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia

NCT01158885
TERMINATED Phase 1

Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL

NCT00981799
COMPLETED Phase 1

Clofarabine and Low Dose Total Body Irradiation as a Preparative Regimen for Stem Cell Transplant in Leukemia.

NCT01041508
TERMINATED Phase 2

T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML)

NCT00939653
TERMINATED Phase 1

Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)

NCT00928200
COMPLETED Phase 1

Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)

NCT00440726
TERMINATED Phase 1

ABT-751 With Chemotherapy for Relapsed Pediatric ALL

NCT00439296

Phase Distribution

PhaseTrial count
Phase 1 17
Phase 2 2

Therapeutic Areas

Lymphoblastic Leukemia, Acute, Childhood 2
Myelogenous Leukemia, Acute, Childhood 1
Lymphoblastic Lymphoma, Childhood 1
CBL Syndrome 1
JCML 1
JMML 1
Leukemia, Juvenile Myelomonocytic 1
Lymphoma, T-Cell 1
ALL, Childhood 1
MDS 1

What is open in the Therapeutic Advances in Childhood Leukemia Consortium pipeline

2 recruiting of 19 indexed (11% open); 8 completed (42%).

Phase mix: 0 late (III/IV) vs 19 early (I/II) (early-phase heavy).

Top condition: Lymphoblastic Leukemia, Acute, Childhood (2 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Therapeutic Advances in Childhood Leukemia Consortium: open-pipeline peers nationwide

Peers matched on 19 registered trials and 11% open enrollment, not the therapeutic-area sidebar.

Therapeutic Advances in Childhood Leukemia Consortium sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 152025303540 0%5%10%15% Total trials Recruiting share Therapeutic Advances in Childhood Leukemia ConsortiumAlmirall, S.A.Bastyr UniversityChurch & Dwight CompanyCordis USCorewell Health WestEthiconRowan UniversitySaint John's Cancer Institute
Therapeutic Advances in Childhood Leukemia Consortium sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Therapeutic Advances in Childhood Leukemia Consortium sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 19 trials (± recruiting share)

Sponsors near 11% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Therapeutic Advances in Childhood Leukemia Consortium page

19 registered trials is a research-attention snapshot, not an endorsement of Therapeutic Advances in Childhood Leukemia Consortium or any single study.

  • 2 of Therapeutic Advances in Childhood Leukemia Consortium's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Lymphoblastic Leukemia, Acute, Childhood is the condition Therapeutic Advances in Childhood Leukemia Consortium studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Lymphoblastic Leukemia, Acute, Childhood trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Therapeutic Advances in Childhood Leukemia Consortium pipeline card: 19 registered trials from official public datasets.Report a data error.